Cilgavimab
Based on 1 publication(s) in Google Scholar
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 95.00%
- CAS No.: 2420563-99-9
- 분자량:148.82 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cilgavimab
More
Biological Activity
Human IgG1 kappa
Virus
Severe acute respiratory syndrome coronavirus 2
Cilgavimab and Tixagevimab simultaneously bind to distinct, nonoverlapping epitopes of the SARS-CoV-2 spike-protein (S) receptor-binding domain to potently neutralize the virus[1].
Cilgavimab exhibits potent monoclonal antibody neutralization activity, and human ACE2-blocking activity, with IC50s of 10-150 ng/mL, and shows binding ability to either trimeric S2Pecto protein or monomeric SRBD with IC50s of 0.1-10 ng/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
43740600 [NCBI]
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2420563-99-9
-
Appearance Liquid
-
분자량 148.82 kDa
-
Color Colorless to light yellow
-
SMILES
[Cilgavimab]
-
Synonyms
AZD-1061; COV2-2130
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]2026 Dec;15(1):2686472. PMID: 42324717
순도&문서
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Levin MJ, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200. [Content Brief]
[2]. Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cilgavimab Related Classifications
HY-P99604 Related Classifications
Powered by Bioz